Corient Private Wealth LLC Buys 257,174 Shares of Balchem Co. (NASDAQ:BCPC)

Corient Private Wealth LLC raised its stake in shares of Balchem Co. (NASDAQ:BCPC) by 4,678.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 262,671 shares of the basic materials company’s stock after buying an additional 257,174 shares during the quarter. Corient Private Wealth LLC owned about 0.81% of Balchem worth $39,072,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BCPC. Heritage Wealth Management LLC bought a new position in Balchem during the fourth quarter worth about $226,000. DekaBank Deutsche Girozentrale increased its position in shares of Balchem by 71.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 51,300 shares of the basic materials company’s stock valued at $7,662,000 after acquiring an additional 21,300 shares during the last quarter. Sei Investments Co. raised its holdings in Balchem by 7.0% during the third quarter. Sei Investments Co. now owns 121,530 shares of the basic materials company’s stock worth $15,075,000 after acquiring an additional 7,973 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in Balchem during the third quarter valued at approximately $465,000. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its stake in Balchem by 81.3% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 13,000 shares of the basic materials company’s stock valued at $1,613,000 after purchasing an additional 5,829 shares in the last quarter. 87.91% of the stock is owned by institutional investors.

Balchem Stock Performance

BCPC opened at $155.20 on Thursday. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $159.52. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.61 and a quick ratio of 1.72. The company has a market capitalization of $5.03 billion, a PE ratio of 43.84, a price-to-earnings-growth ratio of 3.67 and a beta of 0.72. The business has a fifty day simple moving average of $150.82 and a 200 day simple moving average of $143.85.

Insider Activity

In other Balchem news, SVP Michael Robert Sestrick sold 1,929 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $154.45, for a total value of $297,934.05. Following the transaction, the senior vice president now directly owns 4,878 shares of the company’s stock, valued at approximately $753,407.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Michael Robert Sestrick sold 1,929 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $154.45, for a total transaction of $297,934.05. Following the completion of the transaction, the senior vice president now directly owns 4,878 shares in the company, valued at approximately $753,407.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO William A. Backus sold 9,180 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the transaction, the chief accounting officer now owns 12,914 shares of the company’s stock, valued at $2,019,362.18. The disclosure for this sale can be found here. In the last three months, insiders sold 23,109 shares of company stock worth $3,584,641. 1.25% of the stock is currently owned by company insiders.

Analyst Ratings Changes

BCPC has been the subject of several recent analyst reports. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a report on Friday, May 10th. HC Wainwright raised their price objective on Balchem from $167.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, May 6th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.